Northwire Canada EditionThursday, July 23, 2026
Sign inSubscribe
Northwire
⌕
ALDE 2.81 +0.0% TECK 83.43 +3.4% FVI 11.85 −2.1% SUM 1.32 −0.8% RSMX 0.115 +4.5% STW 0.105 +5.0% PAT 0.250 +0.0% CCM 0.530 +1.9% SGN 0.240 −5.9% CNC 1.49 +1.4% PHNM 0.340 +4.6% LIO 0.145 −9.4% RIO 2.67 −4.5% KG 0.160 +3.2% GEN 0.065 +0.0% ECU 1.66 +9.9% ALDE 2.81 +0.0% TECK 83.43 +3.4% FVI 11.85 −2.1% SUM 1.32 −0.8% RSMX 0.115 +4.5% STW 0.105 +5.0% PAT 0.250 +0.0% CCM 0.530 +1.9% SGN 0.240 −5.9% CNC 1.49 +1.4% PHNM 0.340 +4.6% LIO 0.145 −9.4% RIO 2.67 −4.5% KG 0.160 +3.2% GEN 0.065 +0.0% ECU 1.66 +9.9%
Other

Quantum Biopharma talks PET tracer in MS study

By The Northwire Desk — AI Analysis Aug 08, 2025 · 17:20 QNTM · 39.85 Quantum Biopharma Ltd
QNTM · Price

Executive Summary

  • Quantum Biopharma announced promising preclinical/clinical data from a joint study with Massachusetts General Hospital (MGH) scientists regarding a novel PET tracer, [18F]3F4AP, designed to detect and monitor demyelination in Multiple Sclerosis (MS) patients.
  • The study, published in the European Journal of Nuclear Medicine and Molecular Imaging, indicates the tracer can detect lesion differences not visible via conventional MRI, suggesting its potential as a key biomarker for monitoring myelin integrity.
  • The findings are significant for Quantum Biopharma’s investigational neuroprotective drug, Lucid-21-302 (Lucid-MS), as the tracer may help demonstrate the drug's effectiveness in protecting the myelin sheath.

Key Details

  • Study Subject: Evaluation of the PET tracer [18F]3F4AP in healthy controls and people with MS.
  • Key Findings: The tracer demonstrated excellent properties for imaging the human brain and successfully detected differences across MS lesions that were not visible by conventional magnetic resonance imaging (MRI).
  • Significance: The tracer holds potential as a biomarker to monitor changes in demyelination and myelin changes in response to Quantum Biopharma’s investigational drug, Lucid-21-302.
  • Publication Details: The study was led by Dr. Pedro Brugarolas and Dr. Eric Klawiter of MGH, funded by the National Institutes of Health (NIH), and published on August 5, 2025.
  • Company Context: Quantum Biopharma is developing Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation.

Notable Quotes

  • "The published study shows that the PET tracer is highly promising as a biomarker to detect and monitor lesions in people with MS," said Dr. Andrzej Chruscinski, vice-president, scientific and clinical affairs, at Quantum Biopharma. "The ongoing collaborative study with MGH seeks to further evaluate the imaging agent and its potential to demonstrate the effectiveness of drugs, such as Lucid-21-302 (Lucid-MS), that can protect the myelin sheath in MS."
Read the original news release →

More from Quantum Biopharma Ltd

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other